VISEN Pharmaceuticals Reports P-III Results of Lonapegsomatropin in Children with Growth Hormone Deficiency
Shots:
- The result showed an annualized height velocity of 10.66 cm/yr. vs 9.75 cm/yr. for the daily hGH @52wks. and met its 1EP which showed that lonapegsomatropin (QW) was well tolerated with a safety profile and had superior efficacy to the daily hGH
- The pivotal P-III trial has evaluated lonapegsomatropin in children suffering from growth hormone deficiency in China
- Lonapegsomatropin is a human growth hormone developed by using Ascendis Pharma's TransCon technology and has received the US FDA's and EC’s approval for the same indication in Aug 2021 and Jan 2022 respectively
Ref: PR Newswire | Image: Visen
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
